Melacycle-2 is a combined oral hormonal contraceptive tablet which consists of Desogestrel 0.15 mg + Ethinylestradiol 0.02 mg. Desogestrel is a progestogen and ethinylestradiol is an oestrogen which is used in combined oral contraceptive arrangements. Combined oral contraceptives function usually by preventing ovulation and also produce changes that assist in stopping pregnancy.
Composition
Each Melacycle-2 tablet contains:
- Desogestrel – 0.15 mg
- Ethinylestradiol – 0.02 mg
This combination is equal to a low dose combined oral contraceptive formulation. Medicines that have 150 micrograms of desogestrel and 20 micrograms of ethinylestradiol are regarded as combined oral contraceptive preparations.
How Melacycle-2 Works?
Melacycle-2 contains two female hormones that work together to reduce the likelihood of pregnancy. Desogestrel provides progestogenic activity, while ethinylestradiol provides oestrogenic activity.
Combined hormonal contraceptives primarily prevent pregnancy by inhibiting ovulation. They can also cause changes in cervical mucus and the uterine lining that contribute to contraceptive effectiveness.
For reliable protection, Melacycle-2 should be taken exactly according to the prescribing information and package leaflet. The listed pack contains 21 tablets per blister, while 21-day combined-pill regimens commonly involve taking one active tablet daily for 21 days followed by a scheduled break, according to the specific product instructions.
Key Features of Melacycle-2
Melacycle-2 may be considered by healthcare professionals when a combined oral contraceptive containing desogestrel and ethinylestradiol is appropriate for an individual patient. Its 21-tablet blister format can support a structured daily dosing routine.
As with other combined hormonal contraceptives, suitability should be assessed according to the patient’s medical history, current medicines, risk factors and individual contraceptive needs. Combined hormonal contraceptives are not suitable for everyone.
Safety and Precautions
Although combined oral contraceptives are effective contraceptive options, they are associated with potential risks. One important consideration is venous thromboembolism (VTE), or blood clots in veins. The European Medicines Agency states that the risk of VTE with combined hormonal contraceptives is small but clinically important, and product information includes warnings to help patients and healthcare professionals make informed decisions.
Before using Melacycle-2, patients should consult a qualified doctor or pharmacist, particularly if they have a history of blood clots, certain cardiovascular conditions, migraine with aura, liver disease, or other conditions that may affect the suitability of combined hormonal contraception.
Patients should also inform their healthcare professional about all prescription medicines, over-the-counter medicines and supplements they use. If a tablet is missed, the instructions supplied with the specific product should be followed because contraceptive protection can be reduced when active pills are taken incorrectly.
Melacycle-2 does not protect against sexually transmitted infections (STIs). Condoms may be required for STI protection.
Why Choose Melacycle-2?
Melacycle-2 combines two established hormonal components desogestrel and ethinylestradiol in a single oral tablet. Its clearly defined composition and 21-tablet blister format make it a convenient formulation for patients for whom this type of combined hormonal contraception has been prescribed.
The choice of contraceptive should always be individualised. Healthcare professionals can consider factors such as age, medical history, lifestyle, other medicines, previous contraceptive experience and individual preferences before recommending an appropriate option.
